novo nordisk mash - Search News

Order byBest matchMost fresh

News

Novo Nordisk, MASH and liver

Fierce Pharma · 1d

Novo's Wegovy picks up 3rd indication with key FDA approval in the liver disease MASH

With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug approved in a severe form of fatty liver disease. | The FDA has signed off on an accelerated approval for Novo Nordisk's Wegovy to treat certain adults with metabolic-associated steatohepatitis.

Continue reading

· 4d · on MSN

Novo Nordisk's Wegovy gets accelerated US approval for liver disease MASH

Novo’s Wegovy becomes first GLP-1 drug approved for MASH

Investor's Business Daily on MSN1d

Novo Nordisk Rallied On Wegovy's Newest Approval. But This Rival Rallied More.

Novo Nordisk stock jumped Monday after the FDA approved the company's obesity drug, Wegovy, as a treatment for MASH.

1d

Novo Nordisk's Loss Is Eli Lilly's Gain, And Vice Versa

Novo Nordisk A/S gains momentum with FDA approval for Wegovy and strategic pricing. Click for why Novo outshines Eli Lilly ...

5don MSN

Is Novo Nordisk facing its “Nokia moment”? Stock tumbles to $50 from a year-high of $139 amid disruptive rivals and shifting market forces

Novo Nordisks stock has tumbled from record highs after slashing its 2025 outlook, as fierce competition, leadership changes, ...

5d

The Zacks Analyst Blog Highlights Broadcom, Philip Morris International and Novo Nordisk

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results